Results 11 to 20 of about 181,689 (337)

Tabulation of Myeloid, Lymphoid and Intestinal Malignancies in Crohn’s Disease [PDF]

open access: goldCanadian Journal of Gastroenterology, 2002
A variety of malignant complications occur in Crohn’s disease, and previous studies have recorded an increased intestinal cancer risk. The present investigation tabulated myeloid and lymphoid malignancies compared with intestinal cancers in 1000 ...
Hugh J Freeman
doaj   +2 more sources

Elevated C-reactive protein in asymptomatic Crohn's disease patients. listen to the sound of silence [PDF]

open access: yes, 2017
Bhattacharya et al1 confirmed and extended their previous finding2 indicating that “silent” Crohn’s disease (CD) patients (i.e., asymptomatic patients with elevated C-reactive protein [CRP] level) are a subgroup of patients at the higher risk of ...
CORLETO, Vito Domenico   +3 more
core   +1 more source

Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Patient Perspective

open access: yesCanadian Journal of Gastroenterology and Hepatology, 2015
A series of clinical practice guidelines were recently developed by the Canadian Association of Gastroenterology (CAG) to provide clinicians with recommendations for the medical management of nonhospitalized ulcerative colitis (UC) patients.
A Hillary Steinhart, Aida Fernandes
doaj   +1 more source

Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab

open access: yesThe Korean Journal of Gastroenterology, 2018
Pulmonary extraintestinal manifestation is rare in Crohn’s disease and has been reported in only a few cases. Despite the presence of pulmonary abnormalities in a significant proportion of patients with inflammatory bowel disease, there are only few case
Dongyeol Shin   +6 more
doaj   +1 more source

Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses’ Health Study cohorts [PDF]

open access: yes, 2014
Objective: To examine the association between physical activity and risk of ulcerative colitis and Crohn’s disease. Design: Prospective cohort study. Setting: Nurses’ Health Study and Nurses’ Health Study II.
Ananthakrishnan, Ashwin N   +9 more
core   +1 more source

Dietary intake of inulin-type fructans in active and inactive Crohn’s disease and healthy controls: a case-control study [PDF]

open access: yes, 2015
Background and Aims: Prebiotic inulin-type fructans are widely consumed in the diet and may have contrasting effects in Crohn’s disease by stimulating gut microbiota and/or by generating functional gastrointestinal symptoms.
Ailsa L. Hart   +13 more
core   +1 more source

Serum antibodies in first-degree relatives of patients with IBD: A marker of disease susceptibility? A follow-up pilot-study after 7 years [PDF]

open access: yes, 2005
Introduction: Various disease-specific serum antibodies were described in patients with inflammatory bowel disease and their yet healthy first-degree relatives.
H.P. Török   +29 more
core   +5 more sources

PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites. [PDF]

open access: yes, 2012
Genome-wide association studies identified a PTGER4 expression-modulating region on chromosome 5p13.1 as Crohn's disease (CD) susceptibility region. The study aim was to test this association in a large cohort of patients with inflammatory bowel disease (
Achkar, Jean-Paul   +14 more
core   +19 more sources

Microscopic features of small bowel mucosa of patients with Crohn’s disease

open access: yesBMC Gastroenterology, 2019
Background Double-balloon enteroscopy enables performing numerous small bowel biopsies for pathologic analysis. However, most histopathological characteristics of Crohn’s disease are non-specific characteristics.
Yun Cui   +7 more
doaj   +1 more source

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

open access: yesCase Reports in Gastroenterology, 2019
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s
Taketo Suzuki   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy